A randomized, double-blind, multicenter, phase 3 study to compare the efficacy and safety of BMO-2 (adalimumab) and Humira® (adalimumab) in patients with active rheumatoid arthritis - BMO-2

Trial Profile

A randomized, double-blind, multicenter, phase 3 study to compare the efficacy and safety of BMO-2 (adalimumab) and Humira® (adalimumab) in patients with active rheumatoid arthritis - BMO-2

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Autoimmune disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Biocon
  • Most Recent Events

    • 06 Feb 2017 Planned number of patients changed from 140 to 220.
    • 12 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top